Compare BOOM & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOOM | CRBU |
|---|---|---|
| Founded | 1965 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.8M | 203.9M |
| IPO Year | N/A | 2021 |
| Metric | BOOM | CRBU |
|---|---|---|
| Price | $8.56 | $1.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.50 | $8.50 |
| AVG Volume (30 Days) | 159.1K | ★ 1.1M |
| Earning Date | 02-23-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $618,683,000.00 | $9,295,000.00 |
| Revenue This Year | N/A | $0.22 |
| Revenue Next Year | $1.52 | $4.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.46 | $0.66 |
| 52 Week High | $9.92 | $3.54 |
| Indicator | BOOM | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 68.53 | 43.09 |
| Support Level | $8.30 | $1.39 |
| Resistance Level | $9.20 | $1.65 |
| Average True Range (ATR) | 0.37 | 0.09 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 70.76 | 32.93 |
DMC Global Inc operates a diversified family of technical product and process businesses serving the energy, industrial and infrastructure markets. Its business is organized into three segments: Arcadia, DynaEnergetics, and NobelClad. Arcadia Products supplies architectural building products, including exterior and interior framing systems, windows, urtain walls, storefronts etc to the commercial construction market. NobelClad is involved in the production of explosion-welded clad metal plates for use in the construction of corrosion-resistant industrial processing equipment and specialized transition joints. DynaEnergetics driver, designs manufactures and distributes products utilized by the oil and gas industry principally for the perforation of oil and gas wells.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.